Johnson & Johnson Protagonist Therapeutics, Inc Transaction History
Johnson & Johnson
- $293 Million
- Q4 2024
A detailed history of Johnson & Johnson transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Johnson & Johnson holds 2,449,183 shares of PTGX stock, worth $88.2 Million. This represents 32.24% of its overall portfolio holdings.
Number of Shares
2,449,183
Previous 2,449,183
-0.0%
Holding current value
$88.2 Million
Previous $110 Million
14.11%
% of portfolio
32.24%
Previous 35.09%
Shares
1 transactions
Others Institutions Holding PTGX
# of Institutions
254Shares Held
58.9MCall Options Held
226KPut Options Held
218K-
Farallon Capital Management LLC San Francisco, CA5.93MShares$213 Million1.22% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$207 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.5MShares$198 Million3.46% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.22MShares$152 Million0.0% of portfolio
-
State Street Corp Boston, MA3.33MShares$120 Million0.01% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $1.77B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...